Ethical issues in the relationships involving medicine and industryThe timely editorial by P. Komesaroff indicated the wide range of conflicts and cooperation that can arise in the interaction between the pharmaceutical industry and medical practitioners. 1 The issue of drug company sponsorship of research and publications could be an area where both groups are able to cooperate and to provide complementary benefits for patients. Some of these issues were discussed in an editorial in The Lancet in 2001. 2 We responded to that editorial by presenting a survey that we had performed on the conclusions reached in trials which had directly compared two commonly prescribed inhaled glucocorticosteroid drugs, made by direct competitors. These drugs are of more or less equal efficacy. The conclusions were evaluated in a blinded manner after which the identity of the sponsoring company was revealed. Of 76 original research articles identified fulfilling these criteria, only one favoured the drug manufactured by the company's competitor ( P < 0.0001). Thus, the results of these studies are clearly influenced by the sponsoring organization. 3 This is despite the fact that the results of such trials are often published in peer-review journals and the funding source is acknowledged.Ideally trials for such drugs would be better served by separating the funding source from the study itself. It is quite clear that interpretation of the results is not carried out in an objective manner and is unduly influenced by the sponsor. Such issues are being debated elsewhere, but a greater impartiality is needed in the interpretation of the results of trials. 4 In addition to a register of trials to ensure that 'negative' trials are in the public domain, a more rigorous scrutiny on interpretation is also required.